Compounds > fingolimod hydrochloride
Page last updated: 2024-09-02

fingolimod hydrochloride and Carcinoma, Non-Small Cell Lung

fingolimod hydrochloride has been researched along with Carcinoma, Non-Small Cell Lung in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Castagné, V; Debasly, S; Froget, G; Genest, L; Rupp, T1
Chen, M; Chen, T; Hu, T; Li, Y; Ren, H; Yang, T1
Booth, L; Dent, P; Poklepovic, A; Roberts, JL; Spiegel, S1
Hino, H; Hiramoto, M; Kazama, H; Lorenzo, A; Miyazawa, K; Moriya, S; Okuma, T; Ota, K; Takano, N; Yokota, A1
Gu, Y; He, Z; Liu, H; Lu, M; Wang, C; Wang, H; Yin, J; Zhang, Z; Zheng, G1

Other Studies

5 other study(ies) available for fingolimod hydrochloride and Carcinoma, Non-Small Cell Lung

ArticleYear
Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models.
    International journal of molecular sciences, 2022, Jul-25, Volume: 23, Issue:15

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lung Neoplasms; Mice; Tumor Microenvironment

2022
Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
    Oncology reports, 2018, Volume: 39, Issue:2

    Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Microtubule-Associated Proteins; Xenograft Model Antitumor Assays

2018
Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.
    Cancer biology & therapy, 2019, Volume: 20, Issue:5

    Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein 5; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Fingolimod Hydrochloride; Gene Knockdown Techniques; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; RNA, Small Interfering

2019
Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
    Oncology reports, 2019, Volume: 42, Issue:1

    Topics: A549 Cells; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fingolimod Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Sorafenib

2019
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Oncotarget, 2015, Jun-20, Volume: 6, Issue:17

    Topics: Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Disease Progression; DNA-Binding Proteins; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Histone Chaperones; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Matrix Metalloproteinase 9; Mice; Neoplasm Staging; Prognosis; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Transplantation, Heterologous

2015